Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Xeloda Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Prior Authorization Drug Guidelines: Xeloda (capecitabine)

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This archived policy governs prior authorization and clinical criteria for oral capecitabine used in metastatic breast cancer and colorectal cancer. It applies to providers requesting coverage through Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyXeloda (capecitabine) prior authorization
    Policy CodePolicy N/A
    Change TypePolicy retired
    Effective DateJanuary 24, 2017
    Last ReviewJan 31, 2023
    Next Review DateN/A
    Key ActionObtain prior authorization and submit the diagnosis, applicable prior treatment history, and baseline platelet and neutrophil counts meeting policy thresholds.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2covered cancer disease categories
    5,600 mg/dayspecified dose
    ≥100,000/mm³minimum platelet count
    ≥1,500/mm³minimum neutrophil count

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Archived 1/31/2023
    policy status

    Covered Indications and Requirements

    Metastatic breast cancer

    Covered for metastatic breast cancer when one of the following treatment pathways is met.

    Metastatic breast cancer pathways

    • Monotherapy after resistance: Monotherapy for metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing regimen, or resistant to paclitaxel when further anthracycline therapy is not indicated.
    • Combination therapy after anthracycline failure: Combination therapy with docetaxel for metastatic breast cancer after failure of a prior anthracycline-containing regimen.

    Metastatic or adjuvant colorectal cancer

    Covered for colorectal cancer when one of the following treatment pathways is met.

    Colorectal cancer pathways

    • Metastatic colorectal cancer: First-line treatment of metastatic colorectal cancer when treatment with a fluoropyrimidine alone is preferred.
    • Adjuvant Dukes' C colon cancer: Adjuvant therapy of Dukes' C colon cancer after complete resection of the primary tumor when fluoropyrimidine therapy alone is preferred.

    Dosing and baseline laboratory criteria

    Before capecitabine initiation, the stated dosing and laboratory criteria must be met.

    Initiation safety and dosing criteria: For the specified labeled indications, use the stated dose and confirm adequate baseline blood counts before initiation.Dose: 5,600 mg/day in 2 divided doses for body surface area ≥2.18 m²; platelets ≥100,000/mm³; neutrophils ≥1,500/mm³

    Refer to product labeling for dosing details.

    Use of capecitabine in cancers other than the policy-listed breast and colorectal cancer indications is considered off-label. Such requests are not evaluated under these standard coverage criteria and must be reviewed under the VCHCP Coverage of Prescription Medication for Off-Label Use policy.

    Clinical Thresholds for Authorization

    Baseline Platelet Count
    Minimum platelet count≥100,000/mm³
    TimingRequired before capecitabine initiation
    ApplicabilityBaseline hematologic criterion for capecitabine initiation
    Baseline Neutrophil Count
    Minimum neutrophil count≥1,500/mm³
    TimingRequired before capecitabine initiation
    ApplicabilityBaseline hematologic criterion for capecitabine initiation

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Preauthorization is required before initiating capecitabine (Xeloda). Submit documentation supporting a covered indication and the applicable treatment regimen.

    • Metastatic breast cancer: monotherapy after resistance to both paclitaxel and an anthracycline-containing regimen, or after paclitaxel when further anthracycline therapy is not indicated.
    • Metastatic breast cancer: combination therapy with docetaxel after failure of a prior anthracycline-containing regimen.
    • Metastatic colorectal cancer: first-line treatment when fluoropyrimidine monotherapy is preferred, or adjuvant treatment of Dukes' C colon cancer after complete resection when fluoropyrimidine monotherapy is preferred.
    Documentation Required

    Clinical Documentation for Authorization

    Provide complete clinical documentation with the authorization request so the plan can verify the diagnosis, treatment setting, prior therapy, and regimen requested.

    Medication Background

    Capecitabine (Xeloda) is an orally administered fluoropyrimidine carbamate and systemic prodrug that is converted to 5-fluorouracil, an antineoplastic agent. The policy addresses its use in metastatic breast cancer and colorectal cancer, including monotherapy, selected combination therapy, and adjuvant treatment settings. Important clinical safety considerations include bone marrow suppression, cardiotoxicity, hepatotoxicity, diarrhea, hand-foot syndrome, and potentiation of warfarin effects.

    Policy Terms

    Capecitabine
    MedicationXeloda (capecitabine)
    Drug classFluoropyrimidine carbamate
    Antineoplastic activityCapecitabine has antineoplastic activity
    ConversionAn orally administered systemic prodrug converted to 5-fluorouracil
    Metastatic
    TermMetastatic
    DefinitionTreatment of cancer that has spread beyond the primary site

    Initial Therapy Requirements

    Initial therapy

    Initial therapy must meet an approved disease-specific indication and the baseline dosing and laboratory requirements.

    Initial capecitabine authorization: The request is for a listed breast or colorectal cancer indication, applicable prior therapy requirements are documented, and baseline counts meet the policy thresholds.Platelets ≥100,000/mm³; neutrophils ≥1,500/mm³

    For specified labeled indications, the policy states 5,600 mg/day in 2 divided doses for body surface area ≥2.18 m²; refer to product labeling for dosing details.

    Medication Quantity Limit

    Capecitabine Quantity Limit
    Daily quantity limit5,600 mg/day
    AdministrationIn 2 divided doses
    Applicable body surface areaPatients with a body surface area of ≥2.18 m²
    Indication scopeFor labeled indications
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyXeloda (capecitabine) prior authorization
    Policy CodePolicy N/A
    Change TypePolicy retired
    Effective DateJanuary 24, 2017
    Last ReviewJan 31, 2023
    Next Review DateN/A
    Key ActionObtain prior authorization and submit the diagnosis, applicable prior treatment history, and baseline platelet and neutrophil counts meeting policy thresholds.
    SourceLink
    On This Page
    Covered Indications and RequirementsClinical Thresholds for AuthorizationAuthorization and Documentation RequirementsMedication BackgroundPolicy TermsInitial Therapy RequirementsMedication Quantity Limit
    Body Surface Area for Specified Dosing
    Minimum body surface area≥2.18 m²
    Specified dose5,600 mg/day in 2 divided doses
    ApplicabilityFor labeled indications
    • Document the specific cancer diagnosis and whether treatment is metastatic, first-line, or adjuvant after complete resection.
    • For metastatic breast cancer monotherapy, document prior paclitaxel and anthracycline-containing therapy and resistance, or why further anthracycline therapy is not indicated.
    • For combination therapy, document that capecitabine will be used with docetaxel and that a prior anthracycline-containing regimen failed.
    • Identify whether fluoropyrimidine monotherapy is preferred for the requested colorectal cancer treatment.
    Denial Risk

    Denial Risk: Unsupported Use or Inadequate Baseline Counts

    Authorization may be denied when the requested use is not one of the supported indications or when baseline laboratory values do not meet the initiation requirements.

    • Before capecitabine initiation, document baseline platelets of ≥100,000/mm³.
    • Before capecitabine initiation, document baseline neutrophils of ≥1,500/mm³.
    • Requests for unsupported cancer indications or regimens that do not document the required prior treatment history may not meet coverage criteria.
    • For labeled indications, the dosing guidance is 5,600 mg/day in two divided doses for patients with a body surface area of ≥2.18 m²; refer to product labeling for dosing details.
    Note

    Other Cancers Require Off-Label Review

    Use of capecitabine for cancers other than the listed breast and colorectal cancer indications is off-label and must be reviewed under the VCHCP Coverage of Prescription Medication for Off-Label Use policy.

    • Route requests for other cancer indications through the related off-label medication policy and include the supporting clinical rationale and documentation.
    Policy applicationIncludes metastatic breast cancer and metastatic colorectal cancer
    Adjuvant Colorectal Cancer Therapy
    TermAdjuvant colorectal cancer therapy
    Disease stageDukes' C colon cancer
    Surgical statusAfter complete resection of the primary tumor
    Treatment preferenceWhen fluoropyrimidine therapy alone is preferred